BEIJING, April 30, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccine products in China, announced today that it has filed its 2012 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2012 on April 30, 2013. The Annual Report on Form 20-F is now available on the Company's website under SEC Filing in the Investor Relations section. The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge. Requests for a hard copy of the 2012 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing details on the request form. About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza and mumps, as well as animal rabies vaccine. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot, and mouth disease), pneumococcal conjugate, pneumococcal polysaccharides, varicella and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac was also granted a license to commercialize seasonal flu vaccine in Mexico. Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law. Contact: Helen Yang/ Chris LeeSinovac Biotech Ltd. Tel: +86-10-8279-9659/ 9696Fax: +86-10-6296-6910 Email: email@example.com Investors Stephanie Carrington The Ruth Group Tel: +1-646-536-7017 Email: firstname.lastname@example.org Media Victoria Aguiar The Ruth Group Tel: +1-646-536-7013 Email: email@example.com SOURCE Sinovac Biotech Ltd.